Background/Aims: Although recombinant human growth hormone (rhGH) is not approved to treat short stature of achondroplasia (ACH), some studies suggested growth improvement during short-term rhGH treatment. Methods: A meta-analysis of rhGH therapy efficacy in ACH children was performed. Results: From 12 English-language studies, 558 (54.0% males) rhGH-treated ACH children were enrolled. Administration of rhGH (median dosage 0.21 mg/kg/ week; range 0.16-0.42 mg/kg/week) improved height (Ht) from baseline [-5.069 standard deviation score (SDS; 95% CI -5.109 to -5.029); p < 0.0001] to 12 [-4.325 SDS (95% CI -4.363 to -4.287); p < 0.0001] and 24 months [-4.073 SDS (95% CI -4.128 to -4.019); p < 0.0001]. Then, Ht remained approximately constant up to 5 years [-3.941 SDS (95% CI -4.671 to -3.212); p < 0.0001]. Conclusions: In ACH children, rhGH treatment increased Ht from -5.0 to -4.0 SDS during 5 years, but insufficient data are available on both the adult Ht and the changes of body proportions.

1.
Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000;21:23-39.
2.
Horton WA, Hall JG, Hecht JT: Achondroplasia. Lancet 2007;370:162-72.
3.
Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG: Standard growth curves for achondroplasia. J Pediatr 1978;93:435-438.
4.
Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995;9:321-328.
5.
Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995;10:357-359.
6.
Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA: A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999;64:722-731.
7.
Horton WA, Lunstrum GP: Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev Endocr Metab Disord 2002;3:381-385.
8.
Kant SG, Cervenkova I, Balek L, Trantirek L, Santen GW, de Vries MC, van Duyvenvoorde HA, van der Wielen MJ, Verkerk AJ, Uitterlinden AG, Hannema SE, Wit JM, Oostdijk W, Krejci P, Losekoot M: A novel variant of FGFR3 causes proportionate short stature. Eur J Endocrinol 2015;172:763-770.
9.
Ganel A, Horoszowski H: Limb lengthening in children with achondroplasia. Differences based on gender. Clin Orthop Relat Res 1996;332:179-183.
10.
Aldegheri R, Dall'Oca C: Limb lengthening in short stature patients. J Pediatr Orthop B 2001;10:238-247.
11.
Mørch ET: Chondrodystrophic Dwarfs in Denmark. Copenhagen, Munksgaard, 1941.
12.
Stamoyannou L, Karachaliou F, Neou P, Papataxiarchou K, Pistevos G, Bartsocas CS: Growth and growth hormone therapy in children with achondroplasia: a two-year experience. Am J Med Genet 1997;72:71-76.
13.
Seino Y, Yamanaka Y, Shinohara M, Ikegami S, Koike M, Miyazawa M, Inoue M, Moriwake T, Tanaka H: Growth hormone therapy in achondroplasia. Horm Res 2000;53:53-56.
14.
Hagenäs L, Ritzén M, Eklöf O, Neumeyer L, Ollars B, Karlsson E, Müller J, Hertel NT; Swedish Study Group for GH treatment: First year response of growth in short children with achondroplasia or hypochondroplasia treated with growth hormone (GH). Pediatr Res 1993;33:S40.
15.
Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y: Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function and genotype. Eur J Endocrinol 1998;138:275-280.
16.
Kodama H, Okabe I, Yanagisawa M: Therapeutic benefit of growth hormone in achrondroplastic dwarfism. Acta Paediatr Jpn 1990;32:323-324.
17.
Okabe T, Nishikawa K, Miyamori C, Sato T: Growth-promoting effect of human growth hormone on patients with achondroplasia. Acta Paediatr Jpn 1991;33:357-362.
18.
Horton WA, Hecht JT, Hood OJ, Marshall RN, Moore WV, Hollowel JG: Growth hormone therapy in achondroplasia. Am J Med Genet 1992;42:667-670.
19.
Shohat M, Tick D, Barakat S, Bu X, Melmed S, Rimoin DL: Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 1996;81:4033-4037.
20.
Seino Y, Yamate T, Kanzaki S, Kubo T, Tanaka H: Achondroplasia: effect of growth hormone in 40 patients. Clin Pediatr Endocrinol 1994;3:41-45.
21.
Bridges NA, Brook CGD: Progress report: growth hormone in skeletal dysplasia. Horm Res 1994;42:231-234.
22.
Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino Y: Efficacy of growth hormone therapy for patients with skeletal dysplasia. J Bone Miner Metab 2003;21:307-310.
23.
Ramaswami U, Rumsby G, Spoudeas HA, Hindmarsh PC, Brook CG: Treatment of achondroplasia with growth hormone: six years of experience. Pediatr Res 1999;46:435-439.
24.
Hertel NT, Eklöf O, Ivarsson S, Aronson S, Westphal O, Sipilä I, Kaitila I, Bland J, Veimo D, Müller J, Mohnike K, Neumeyer L, Ritzen M, Hagenäs L: Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr 2005;94:1402-1410.
25.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
26.
Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions - Version 5.1.0. Hoboken, Wiley, 2011.
27.
Massart F, Bizzi M, Baggiani A, Miccoli M: Height outcome of the recombinant human growth hormone treatment in patients with SHOX gene haploinsufficiency: a meta-analysis. Pharmacogenomics 2013;14:607-612.
28.
Massart F, Bertelloni S, Miccoli M, Baggiani A: Height outcome of the recombinant human growth hormone treatment in subjects with Noonan syndrome: a meta-analysis. J Genet Syndr Gene Ther 2014;5:1-7.
29.
Massart F, Miccoli M, Baggiani A, Bertelloni S: Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics 2015;16:1965-1973.
30.
Hagenäs L, Ritzén EM, Eklöf O, Neumeyer L, Ollars B, Muller J, Hertel NT, Sipilä I, Kaitila I, Aagenaes Ø, Mohnike C: Two year results on growth hormone treatment in prepubertal children with achondroplasia and hypochondroplasia - a dose study. Horm Res 1996;46:S27.
31.
Tanaka N, Katsumata N, Horikawa R, Tanaka T: The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J 2003;50:69-75.
32.
Vihervuori E, Virtanen M, Koistinen H, Koistinen R, Seppälä M, Siimes MA: Hemoglobin level is linked to growth hormone-dependent proteins in short children. Blood 1996;87:2075-2081.
33.
Key LL Jr, Gross AJ: Response to growth hormone in children with chondrodysplasia. J Pediatr 1996;128:S14-S17.
34.
Alatzoglou KS, Hindmarsh PC, Brain C, Torpiano J, Dattani MT: Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochondroplasia due to FGFR3 mutations. J Clin Endocrinol Metab 2009;94:3959-3963.
35.
Ono T, Tanaka H, Moriwake T, Kanzaki S, Seino Y: Achondroplasia associated with pelvic lipomatosis. Lancet 1999;353:1017.
36.
Hertel T: Growth hormone treatment in skeletal dysplasia: the KIGS experience; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics: 20 Years of KIGS. Basel, Karger, 2009, pp 356-368.
37.
Gershberg H, Neumann L, Mari S: Human growth hormone in vitamin D-resistant rickets and achondroplastic dwarfism. Fed Proc 1962;21:198.
38.
Gershberg H, Mari S, Hulse M, St. Paul H: Long-term treatment of hypopituitary and of achondroplastic dwarfism with human growth hormone. Metabolism 1964;13:152-160.
39.
Escamilla RF, Hutchings JJ, Li CH, Forsham P: Achondroplastic dwarfism. Effects of treatment with human growth hormone. Calif Med 1966;105:104-110.
40.
Horton WA, Howard CP, Grunt JA: Skeletal changes following growth hormone treatment in a child with combined hypopituitarism and a skeletal dysplasia. Acta Endocrinol (Copenh) 1983;103:302-308.
41.
Raes M, Vanderschueren-Lodeweyckx M, Haspeslagh M, Vles JS, Fryns JP, Eeckels R: A boy with acromesomelic dysplasia. Growth course and growth hormone release. Helv Paediatr Acta 1985;40:415-420.
42.
Goldstein SJ, Wu RH, Thorpy MJ, Shprintzen RJ, Marion RE, Saenger P: Reversibility of deficient sleep entrained growth hormone secretion in a boy with achondroplasia and obstructive sleep apnea. Acta Endocrinol (Copenh) 1987;116:95-101.
43.
Bozzola M, Cisternino M, Biscaldi I, Maghnie M, Valtorta A, Moretta A, Severi F: Effectiveness of growth hormone (GH) therapy in GH-deficient children and non-GH-deficient short children. Eur J Pediatr 1988;147:248-251.
44.
Downs AM, Kennedy CT: Somatotrophin-induced acanthosis nigricans. Br J Dermatol 1999;141:390-391.
45.
Burren CP, Werther GA: Skeletal dysplasias: response to growth hormone therapy. J Pediatr Endocrinol Metab 1996;9:31-40.
46.
Yamate T, Kanzaki S, Tanaka H, Kubo T, Moriwake T, Inoue M, Seino Y: Growth hormone (GH) treatment in achondroplasia. J Ped Endocrinol 1993;6:45-52.
47.
Seino Y, Moriwake T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H: Molecular defects in achondroplasia and the effects of growth hormone treatment. Acta Paediatr Suppl 1999;88:118-120.
48.
Weber G, Prinster C, Meneghel M, Russo F, Mora S, Puzzovio M, Del Maschio M, Chiumello G: Human growth hormone treatment in prepubertal children with achondroplasia. Am J Med Genet 1996;61:396-400.
49.
Nishi Y, Kajiyama M, Miyagawa S, Fujiwara M, Hamamoto K: Growth hormone therapy in acondroplasia. Acta Endocrinologica 1993;128:394-396.
50.
Liu J, Tang X, Cheng J, Wang L, Yang X, Wang Y: Analysis of the clinical and molecular characteristics of a child with achondroplasia: a case report. Exp Ther Med 2015;9:1763-1767.
51.
Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L: Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 2012;91:1108-1114.
52.
Yamashita A, Morioka M, Kishi H, Kimura T, Yahara Y, Okada M, Fujita K, Sawai H, Ikegawa S, Tsumaki N: Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 2014;513:507-511.
53.
Fredriks AM, van Buuren S, van Heel WJ, Dijkman-Neerincx RH, Verloove-Vanhorick SP, Wit JM: Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders. Arch Dis Child 2005;90:807-812.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.